# Pelvic Pain and Depression

> **NIH NIH U01** · NORTHWESTERN UNIVERSITY · 2021 · $1

## Abstract

PROJECT SUMMARY
Urologic Chronic Pelvic Pain Syndrome (UCPPS) encompasses two highly prevalent chronic urologic pain disorders,
interstitial cystitis/ bladder pain syndrome (IC/BPS) in men and women, and chronic prostatitis/chronic pelvic pain
syndrome (CP/CPPS) in men. Like many chronic pain disorders, UCPPS is poorly understood and characterized, and
treatment is mostly empirical and unsatisfactory. The Multidisciplinary Approach to the Study of Chronic Pelvic Pain
(MAPP) Research Network was established by the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), to study the etiology and treated natural history of UCPPS, to inform better treatments and management
of symptoms through improved designs of clinical trials, and to identify clinical factors and research measurements
to define clinically relevant sub-groups of these patients.
The MAPP Research Network is currently completing enrollment of participants into the Trans-MAPP Symptom
Patterns Study (SPS), which involves integrated phenotyping of UCPPS participants at baseline and during a 36-
month longitudinal, observational period. The SPS includes measures to refine UCPPS subgrouping, identify
symptom trends, and discover associated risk factors and biological correlates to progression profiles. Integrated
within the central protocol are studies to correlate clinical and biological profiles with response to selected UCPPS
therapies (the Analysis of Therapies during Longitudinal Assessment of Symptoms [ATLAS] study). The current
funding period ends in June 2019. We propose a three-year funding extension, through June 2022.
During the proposed three-year extension, we aim to accomplish the following:
SPECIFIC AIM 1: To Obtain an Additional 12 Months of Follow-up in the MAPP-II SPS. The MAPP-II SPS was
designed to follow UCPPS participants for up to three years. By extending the timeframe for longitudinal follow-up
from July 2019 to July 2020, the number of UCPPS participants followed for three years in the SPS will almost
double (from 198 to 384). This additional data will substantially increase the ability of MAPP investigators to
examine patterns and predictors of UCPPS symptoms over time.
SPECIFIC AIM 2: To Observe Additional ATLAS Events in the MAPP-II SPS. A major focus of the MAPP-II SPS is to
correlate individual participant phenotypes with UCPPS treatment response. To accomplish this, SPS participants
complete a phenotyping assessment before and after starting new UCPPS treatments (ATLAS study). The
additional year of follow-up will provide time for new treatment `events' to occur which can be included in this
important analysis.
SPECIFIC AIM 3: To Conduct Analyses of MAPP-II Data. The current funding period provides inadequate time for
MAPP investigators to analyze the data collected as part of the SPS. Therefore, the final two years of the proposed
three-year MAPP-II extension will be devoted exclusively to data analysis and manuscript preparation.

## Key facts

- **NIH application ID:** 10206105
- **Project number:** 5U01DK082342-13
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** David J Klumpp
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1
- **Award type:** 5
- **Project period:** 2008-09-15 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10206105

## Citation

> US National Institutes of Health, RePORTER application 10206105, Pelvic Pain and Depression (5U01DK082342-13). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10206105. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*